[1] SHINGADE G M,AAMER Q,SABALE P M,et al. Review on: Recent trend on transdermal drug delivery system[J]. J Drug Deliv, 2012,2(1):66-75. [2] PATIL P M,CHAUDHRI P D,PATEL J K,et al. Recent trends in challenges and opportunities of transdermal drug delivery system[J]. Int J Drug Dev Res,2012,4(1):39-50.[3] GOSWAMI D S. Permeation enhancer for TDDS from natural and synthetic sources: A review[J].J Biomed Pharm Res,2013,2(1):19-29.[4] NASROLLAHI S A,TAGHIBIGLOU C,AZIZI E,et al. Cell-penetrating peptides as a novel transdermal drug delivery system[J]. Chem Biol Drug Des,2012,80(5):639-646.[5] ME M,LANGEL . Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery[J]. Curr Opin Pharmacol,2006,6(5):509-514.[6] NAKASE I,TANAKA G,FUTAKI S. Cell-penetrating peptides (CPPs) as a vector for the delivery of siRNAs into cells[J]. Mol Biosyst,2013,9(5):855-861.[7] KAMEI N,MORISHITA M,EDA Y,et al. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption[J]. J Controlled Release,2008,132(1):21-25.[8] GREEN M,LOEWENSTEIN P M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein[J]. Cell,1988,55(6):1179-1188.[9] GREEN M,ISHINO M,LOEWENSTEIN P M. Mutational analysis of HIV-1 Tat minimal domain peptides: Identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression[J]. Cell,1989,58(1):215-223.[10] BECHARA C,SAGAN S. Cell-penetrating peptides: Twenty years later, where do we stand [J]. FEBS Lett,2013,587(12):1693-1702.[11] WANG P,LIU M,GUO Y M. Development of cell-penetrating peptide applying as a vector in molecular imaging[J]. J Med Imaging(医学影像学杂志),2008,18(5):565-568.[12] CAO Y,LI Y,WANG Y,et al. Preparation of lidocaine hydrochloride-loaded transactivation transcriptional activator conjugated polymeric liposomes and its in vitro skin permeation in mice[J]. Tianjin Med J(天津医药),2013,41(3):227-229.[13] PATLOLLA R R,DESAI P R,BELAY K,et al. Translocation of cell penetrating peptide engrafted nanoparticles across skin layers[J]. Biomaterials,2010,31(21):5598-5607.[14] MANOSROI J,LOHCHAROENKAL W,GTZ F,et al. Transdermal absorption and stability enhancement of salmon calcitonin by Tat peptide[J]. Drug Dev Ind Pharm,2013,39(4):520-525.[15] UCHIDA T,KANAZAWA T,TAKASHIMA Y,et al. Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002[J]. Chem Pharm Bull(Tokyo),2011,59(2):196-201.[16] LIN C M,HUANG K,ZENG Y,et al. A simple, noninvasive and efficient method for transdermal delivery of siRNA[J]. Arch Dermatol Res,2012,304(2):139-144.[17] SUN Z,WEN L P. Transdermal delivery of fusion green fluorescent protein mediated by covalently associated TD1 peptide[J]. J Univ Sci Technol Chin(中国科技大学学报),2009,39(4):344-350.[18] CHEN Y,SHEN Y,GUO X,et al. Transdermal protein delivery by a coadministered peptide identified via phage display[J]. Nat Biotechnol,2006,24(4):455-460.[19] ROTHBARD J B,GARLINGTON S,LIN Q,et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation[J]. Nat Med,2000,6(11):1253-1257.[20] SHAH P P,DESAI P R,CHANNER D,et al. Enhanced skin permeation using polyarginine modified nanostructured lipid carriers[J].J Controlled Release,2012,161(3):735-745.[21] YI X,ZHAO G,ZHANG H,et al. MITF-siRNA formulation is a safe and effective therapy for human melasma[J]. Mol Ther,2010,19(2):362-371.[22] CHOI J K,JANG J H,JANG W H,et al. The effect of epidermal growth factor (EGF) conjugated with low-molecular-weight protamine (LMWP) on wound healing of the skin[J]. Biomaterials,2012,33(33):8579-8590.[23] LOPES L B,BROPHY C M,FURNISH E,et al. Comparative study of the skin penetration of protein transduction domains and a conjugated peptide[J]. Pharm Res,2005,22(5):750-757.[24] JOHNSON L N,CASHMAN S M,READ S P,et al. Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skin[J]. Vision Res,2010,50(7):686-697.[25] NASROLLAHI S A,FOULADDEL S,TAGHIBIGLOU C,et al. A peptide carrier for the delivery of elastin into fibroblast cells[J]. Int J Dermatol,2012,51(8):923-929.[26] DESAI P R,MAREPALLY S,PATEL A R,et al. Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo[J]. J Controlled Release,2013,170(1):51-63.[27] GOLDBERG M S. siRNA delivery for the treatment of ovarian cancer[J]. Methods,2013,63(2):95-100.[28] HUANG Z Y,KIM M K,KIM-HAN T H,et al. Effect of locally administered Syk siRNA on allergen-induced arthritis and asthma[J]. Mol Immunol,2013,53(1):52-59.[29] VICENTINI F T,BORGHETI-CARDOSO L N,DEPIERI L V,et al. Delivery systems and local administration routes for therapeutic siRNA[J]. Pharm Res,2013,30(4):915-931.[30] UCHIDA T,KANAZAWA T,KAWAI M,et al. Therapeutic effects on atopic dermatitis by anti-RelA short interfering RNA combined with functional peptides Tat and AT1002[J]. J Pharmacol Exp Ther,2011,338(2):443-450.[31] OOKUBO N,MICHIUE H,KITAMATSU M,et al. The transdermal inhibition of melanogenesis by a cell-membrane-permeable peptide delivery system based on poly-arginine[J]. Biomaterials,2014,35(15):4508-4516.[32] HOU Y W,CHAN M H,HSU H R,et al. Transdermal delivery of proteins mediated by non-covalently associated arginine-rich intracellular delivery peptides[J]. Exp Dermatol,2007,16(12):999-1006.[33] CANDAN G,MICHIUE H,ISHIKAWA S,et al. Combining poly-arginine with the hydrophobic counter-anion 4-(1-pyrenyl)-butyric acid for protein transduction in transdermal delivery[J]. Biomaterials,2012,33(27):6468-6475.[34] CHANG M,LI X,SUN Y,et al. Effect of cationic cyclopeptides on transdermal and transmembrane delivery of insulin[J]. Mol Pharm,2013,10(3):951-957.[35] NAIR B G,FUKUDA T,MIZUKI T,et al. Intracellular trafficking of superparamagnetic iron oxide nanoparticles conjugated with TAT peptide: 3-Dimensional electron tomography analysis[J]. Biochem Biophys Res Commun,2012,421(4):763-767.[36] CHOI Y S,LEE J Y,SUH J S,et al. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine[J]. Biomaterials,2010,31(6):1429-1443.[37] YANG Y,JIANG Y,WANG Z,et al. Skin-permeable quaternary nanoparticles with layer-by-layer structure enabling improved gene delivery[J]. J Mater Chem,2012,22(19):10029-10034.[38] Design and application of some peptides as permeation enhancers for transdermal and transmembrane drug delivery:China,201310052658.2 [P]. 2013-06-12.[39] THORN P E,PERSSON D,ESBJRNER E K,et al. Membrane binding and translocation of cell-penetrating peptides[J]. Biochemistry,2004,43(12):3471-3489.[40] LOPES L B,FURNISH E,KOMALAVILAS P,et al. Enhanced skin penetration of P20 phosphopeptide using protein transduction domains[J]. Eur J Pharm Biopharm,2008,68(2):441-445.[41] SHEN Y Y.The application of phage display technology in transdermal drug delivery and new nanomaterials[D].University of Science and Technology of China(中国科技大学),2009.[42] INAGAKI K,BEGLEY R,IKENO F,et al. Cardioprotection by ε-Protein kinase c activation from ischemia continuous delivery and antiarrhythmic effect of an ε-protein kinase c-activating peptide[J]. Circulation,2005,111(1):44-50.[43] MAGZOUB M,OGLCKA K,PRAMANIK A,et al. Membrane perturbation effects of peptides derived from the N-termini of unprocessed prion proteins[J]. BBA-Biomembranes,2005,1716(2):126-136.